Related Experiment Video
Updated: Jan 9, 2026
06:27
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
1.1K
IDH1 and IDH2 mutations in gliomas
Adam L Cohen1, Sheri L Holmen, Howard Colman
1Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA. adam.cohen@hci.utah.edu
Current Neurology and Neuroscience Reports
|March 28, 2013
Summary
Isocitrate dehydrogenase (IDH) mutations in gliomas drive cancer development and are linked to better patient prognosis. While these IDH mutations are oncogenic, targeted therapies are still under investigation.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Mutations in isocitrate dehydrogenase (IDH) 1 and 2 are prevalent in low-grade gliomas and secondary high-grade gliomas.
- These early-stage gliomagenesis mutations alter enzyme function, leading to the production of the oncometabolite 2-hydroxyglutarate and reduced NADPH generation.
Purpose of the Study:
- To investigate the oncogenic mechanisms of IDH mutations in gliomas.
- To explore the impact of IDH mutations on glioma methylation and prognosis.
- To review current detection methods and therapeutic strategies for IDH-mutated gliomas.
Main Methods:
- Analysis of IDH mutations in glioma samples.
- Biochemical assays to assess enzyme function and metabolite production.
- Immunohistochemistry and magnetic resonance spectroscopy for IDH mutation detection.
Main Results:
- IDH mutations were confirmed as oncogenic, influencing cellular metabolism, redox potential, and gene expression.
- A significant association was observed between IDH mutations and increased glioma methylation.
- Gliomas with mutated IDH1 and IDH2 demonstrated an improved prognosis compared to wild-type IDH gliomas.
Conclusions:
- IDH mutations play a critical role in glioma development and are associated with a better clinical outcome.
- Current detection methods allow for reliable identification of IDH-mutated gliomas.
- Targeting mutated IDH remains a key area for future therapeutic development in glioma treatment.
